Take @ look at this year great news for CCXI
It is just a matter of time before the shareprice will explode.. AIMO
ChemoCentryx Receives European Medicines Agency PRIority MEdicines (PRIME) Designation for Accelerated Assessment of Complement 5a Receptor Inhibitor CCX168 for Treatment of Patients with ANCA-Associated Vasculitis
PRIME designation designed to provide path to expedite clinical development and accelerate marketing authorization applications
ChemoCentryx Inc
ChemoCentryx Appoints Henry A. McKinnell, Jr. to Board of Directors
GlobeNewswire•October 20, 2016
More good news..ChemoCentryx’s CCR2 Inhibitor CCX872 Shown to Reduce Liver Fibrosis in NASH Models
GlobeNewswire•October 18, 2016
ChemoCentryx Announces Presentation of Positive Data from Ongoing Pilot Phase II Trial of CCX168 (Avacopan) in Atypical Hemolytic Uremic Syndrome (aHUS) at ASN Kidney Week 2016
GlobeNewswire•October 17, 2016
ChemoCentryx Announces Positive Top-Line Results for CCX168 from the Phase II ANCA-Associated Vasculitis CLASSIC Study and Advances Plans to Initiate Phase III Development
ChemoCentryx Announces Presentation of Positive Results from Phase II ANCA-Associated Vasculitis CLEAR Trial of Orally Administered Complement 5a Receptor Inhibitor CCX168 at the 53rd ERA-EDTA Congress
ChemoCentryx announces Vifor Pharma has licensed rights to commercialize CCX168 in Europe, Canada, Mexico, Central and South America and South Korea; to receive $85 mln (CCXI) :
ChemoCentryx Receives FDA Orphan Products Development Grant($500000) for Orally Administered Complement 5a Receptor Inhibitor CCX168 for Treatment of ANCA-Associated Vasculitis
ChemoCentryx Announces Positive Results in Phase II ANCA-Associated Vasculitis CLEAR Trial of Orally Administered Complement 5a Receptor Inhibitor CCX168
Chemocentryx, Inc. (Mountain View, California), Petrus Bekker, Phase 2 Study of CCX168 for the Treatment of Anti-Neutrophil Cytoplasmic Auto-Antibodies Associated Vasculitis — $500,000 for one yearh
